Is Cooper Companies (COO) Cheap After Slower Growth Forecasts Raised Valuation Concerns?
Cooper Companies (COO) is considered 5.5% undervalued with a fair value estimate of $80.57, trading at $76.16. The company is expected to see substantial revenue growth from its MyDAY contact lens rollout. However, the stock faces risks from slower MyDAY adoption or weakness in its fertility and Paragard IUD segments, and its P/E ratio of 63x is significantly higher than the industry average of 28x, indicating potential valuation risk.
Stryker Corp Stock (SYK) Closed Down by 3.61% on Aug 20: A Full Analysis
Stryker Corp (SYK) stock closed down by 3.61% on August 20, experiencing profit-taking despite a recent U.S. defense contract modification. Investors remain concerned about operational disruptions, cyber incident costs, supply chain bottlenecks, and the company's ambitious second-half revenue guidance. Despite strong fundamentals and analyst consensus, short-term trading dynamics are influenced by macro-level sector rotations and valuation reassessments.
Intuitive Surgical Inc Stock (ISRG) Moved Down by 4.89% on Aug 20: What Signal Does It Send?
Intuitive Surgical Inc (ISRG) stock fell by 4.89% due to concerns over increasing competition in the robotic-assisted surgery market, regulatory clearances for rival systems, and a cautious full-year guidance despite strong operational metrics. Wall Street analysts also revised price targets downward, reflecting hospital capital expenditure caution and broader market anxieties. Technical indicators show a mix of buy, neutral, and sell signals, with low media attention and generally bullish market sentiment.
Boston Scientific Corp. stock underperforms Thursday when compared to competitors
Shares of Boston Scientific Corp. (BSX) fell 5.08% on Thursday, closing at $49.37. This performance lagged behind the broader market, with the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) also experiencing declines. The stock is now significantly below its 52-week high achieved in September.
Fury Gold Mines Stock Surges 8.54% as Eau Claire Exploration, High-Grade Gold Potential and Quebec Resource Growth Draw Investor Interest
Fury Gold Mines Limited (TSX:FURY) saw an 8.54% surge in its stock, attracting investor attention due to strong precious-metals sentiment and its focus on the Eau Claire gold project in Quebec. The company's strategy revolves around exploration success, resource expansion, and the economic development of its mineral assets, rather than large-scale commercial production. Key factors drawing interest include high-grade gold potential, resource expansion opportunities at Eau Claire, and operating in Quebec, a well-established mining jurisdiction.
Lisanti Capital Growth LLC Acquires Shares of 65,275 Viavi Solutions Inc. $VIAV
Lisanti Capital Growth LLC has acquired 65,275 shares of Viavi Solutions Inc. (NASDAQ:VIAV) for approximately $3.1 million, making it a new position for the institutional investor. Viavi Solutions recently exceeded quarterly earnings and revenue expectations, reporting $0.34 EPS and $443.1 million in revenue, leading to a "Moderate Buy" consensus from analysts. However, significant insider selling, including a director's $3.27 million stock sale, introduces a note of caution despite favorable analyst sentiment.
Global Cardiovascular Devices Market to Reach $101.6 Billion by 2030, Says BCC Research Analyst
The global cardiovascular devices market is projected to grow from $72.4 billion in 2025 to $101.6 billion by 2030, driven by an aging population, increased disease prevalence, and advancements in minimally invasive procedures and remote monitoring. Key trends include the adoption of leadless pacemakers, pulsed field ablation, and AI-enabled cardiac monitoring solutions. Major players like Abbott, Boston Scientific, and Medtronic dominate the market, while innovators introduce next-generation implantable and bioresorbable devices.
Edmond DE Rothschild Holding S.A. Acquires Shares of 875,810 Boston Scientific Corporation $BSX
Edmond DE Rothschild Holding S.A. recently acquired a new stake of 875,810 shares in Boston Scientific Corporation (NYSE:BSX), valued at approximately $37.38 million. This acquisition makes Edmond DE Rothschild Holding S.A. a 0.06% owner of Boston Scientific. Other institutional investors like Vanguard Group Inc., BlackRock Inc., and State Street Corp also made significant adjustments to their holdings in the medical equipment provider.
BioMarin to acquire Alesta Therapeutics for up to $490 million
BioMarin Pharmaceutical Inc. has announced a definitive agreement to acquire Alesta Therapeutics for up to $490 million. The acquisition involves an upfront cash payment of $275 million for Alesta's lead asset, ALE1, a therapy for hypophosphatasia, with potential additional milestone payments of up to $215 million. Existing Alesta shareholders will retain interests in a newly formed entity for non-ALE1 assets, and the transaction is expected to close in Q3 2026.
Boston Scientific Corp. stock outperforms competitors on strong trading day
Shares of Boston Scientific Corp. (BSX) rose 3.05% to $52.01 on Wednesday, outperforming the broader market. This gain snapped a two-day losing streak for the stock. The S&P 500 Index (SPX) increased by 0.21%, and the Dow Jones Industrial Average (DJIA) rose by 0.22% on the same trading day.
Should STERIS’ (STE) Record Chemistries Investment and Reaffirmed Outlook Require Action From Investors?
STERIS plc (STE) recently reported strong Q1 fiscal 2027 results with increased sales and earnings, reaffirmed its full-year revenue growth guidance, and announced a record US$600 million investment in a chemistries Center of Excellence in North Carolina. This investment signals management's confidence in its infection prevention chemistries business and is a key factor to watch, as successful execution could reinforce growth, while delays or cost overruns could highlight regulatory and cost risks. The company's narrative projects significant revenue and earnings growth by 2029, suggesting a potential 13% upside to its current price.
RDAC stock surges as low-float SPAC trading appears to overwhelm fundamentals
RDAC (Rising Dragon Acquisition Corp.) stock surged by 128.9% due to speculative trading in a thinly traded SPAC, rather than new fundamental developments. This price movement is likely driven by a reduced public float and momentum buying, creating a squeeze-like scenario, especially since the company is a blank-check company without an operating business. Institutional investors have significantly reduced their positions in RDAC in recent quarters, indicating a divergence between institutional activity and the recent price surge.
Great Lakes Advisors LLC Makes New Investment in Boston Scientific Corporation $BSX
Great Lakes Advisors LLC has acquired a new stake in Boston Scientific Corporation (NYSE:BSX), purchasing 279,760 shares valued at approximately $11.9 million. This investment comes as institutional ownership in Boston Scientific reaches 89.07% and the company reports strong financial results, including an EPS of $0.86, exceeding estimates, and a $5 billion share repurchase program authorization. Analysts maintain a "Moderate Buy" rating for Boston Scientific with a consensus target price of $71.62.
REG - RTW Biotech Opp. - BioMarin to acquire Alesta Therapeutics
RTW Biotech Opportunities Ltd ("RTW Bio") announced that BioMarin Pharmaceutical Inc. is set to acquire Alesta Therapeutics, a clinical-stage biotechnology company. The deal includes an upfront cash payment of $275 million for Alesta's lead asset, ALE1, which represents a 41% uplift to RTW Bio's carrying value, with potential for an additional $215 million in milestone payments. This marks the sixth acquisition from RTW Bio's portfolio in 2026, validating its strategy of investing in early-stage, differentiated science.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following a notification from the AFM. The announcement details Goldman Sachs Group Inc.'s voting rights in QIAGEN, outlining both real and potential holdings across various share types and methods of disposal. The total capital interest and voting rights held by Goldman Sachs Group Inc. are reported as 3.05%.
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors
Boston Scientific Corp. (BSX) shares fell by 1.87% on Tuesday, closing at $50.47, underperforming its competitors and the broader market. This decline occurred during a generally down trading session, with the S&P 500 Index falling 0.69% and the Dow Jones Industrial Average dropping 0.22%. This marks the second consecutive day of losses for the stock.
Boston Scientific stock holds in the low $51 range as Q2 2026 margins and EPS beat guidance
Boston Scientific's stock is trading in the low $51 range despite the company reporting stronger-than-expected Q2 2026 results, including increased margins and adjusted EPS that surpassed guidance. The medical device group saw its stock decline by 46% from the start of 2026, leading to a significant gap between the current trading price and the average analyst target price of $71.62. The article highlights the company's improved profitability, driven by cardiovascular and electrophysiology franchises, and discusses the implications for investors.
Boston Scientific Stimulator Lawsuit Alleges Spine Implant Caused Nerve Damage, Shocks
A Kentucky man has filed a product liability lawsuit against Boston Scientific, alleging that its spinal cord stimulator caused unexpected electric shocks and permanent nerve damage, despite being marketed for chronic pain relief. The lawsuit claims Boston Scientific knew about the device's "unacceptably high failure rates" but continued to promote it without adequate warnings. This case is part of a larger multidistrict litigation (MDL) against Boston Scientific, with similar consolidations sought for Nevro and Abbott stimulator lawsuits, highlighting widespread concerns about these implanted pain devices.
Mitsubishi UFJ Asset Management Co. Ltd. Buys New Holdings in Boston Scientific Corporation $BSX
Mitsubishi UFJ Asset Management Co. Ltd. has acquired a new stake in Boston Scientific Corporation (NYSE:BSX), purchasing over 3.6 million shares valued at approximately $154.4 million. This move is part of broader institutional investment activity, with other hedge funds also adjusting their positions in the medical equipment provider. Boston Scientific recently reported strong quarterly earnings and authorized a $5 billion share buyback plan, indicating management's confidence in the company's value.
Conway Capital Management Inc. Takes $1.23 Million Position in Boston Scientific Corporation $BSX
Conway Capital Management Inc. has initiated a new position in Boston Scientific Corporation (NYSE:BSX), purchasing 28,750 shares valued at approximately $1.23 million, making it their 25th biggest position. Other institutional investors have also adjusted their holdings in BSX. The company currently holds a "Moderate Buy" rating from analysts with an average target price of $71.62, and recent insider buying activity by executives has been noted.
Boston Scientific (BSX) Faces Growth Concerns in Key Medical Device Franchises
Aristotle Capital Management's Core Equity Fund sold its position in Boston Scientific Corporation (BSX) due to concerns about slowing growth in its key medical device franchises, Watchman and Farapulse. Despite positive clinical trial data, Watchman's growth is declining due to implantation modality changes and market hesitation, while Farapulse faces increased competition. The fund believes it will take time for Boston Scientific to regain investor confidence and its premium valuation.
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences is developing nanosecond pulsed field ablation (nsPFA) technology as a potential treatment for atrial fibrillation (AFib) and other conditions. CEO Paul LaViolette highlighted the non-thermal nature of nsPFA, which aims to ablate cells without causing inflammation or damage to surrounding tissues, potentially offering significant advantages over current methods. The company is enrolling its Nano-Pulse AF IDE study in the U.S., building on promising European feasibility study results that showed a substantial reduction in AFib failure rates compared to existing technologies.
Trivium Point Advisory LLC Invests $1.48 Million in Boston Scientific Corporation $BSX
Trivium Point Advisory LLC has acquired a new stake of 34,578 shares in Boston Scientific Corporation (NYSE:BSX), valued at approximately $1.48 million, according to its latest SEC filing. This comes as other institutional investors have also adjusted their holdings in the medical equipment provider, with Norges Bank and Bank of New York Mellon Corp purchasing new positions. Boston Scientific recently reported strong quarterly earnings, beating analyst estimates, and announced a $5.00 billion share buyback plan, signaling management's belief that the stock is undervalued.
Mill Capital Management LLC Invests $9.85 Million in Boston Scientific Corporation $BSX
Mill Capital Management LLC has invested $9.85 million in Boston Scientific Corporation, acquiring 230,815 shares. Institutional investors collectively own 89.07% of the company's stock, and despite a recent growth slowdown in key businesses, analysts maintain a "Moderate Buy" consensus rating with an average price target of $71.62. Additionally, Boston Scientific's CEO and a director recently increased their holdings through significant share purchases.
Why Alphatec Holdings (ATEC) Is Up 5.9% After Reaffirming 2026 Outlook And Narrowing Q2 Losses
Alphatec Holdings (ATEC) saw its stock rise 5.9% after reporting narrowed Q2 net losses and reaffirming its 2026 revenue guidance of approximately US$882 million. The company also filed a shelf registration for 800,000 common shares. This performance highlights Alphatec's cost discipline and continued investment in growth initiatives, reinforcing its path towards potential sustained profitability despite ongoing competition.
Which Medtech Giant Would Buy Inspire Medical Systems?
Inspire Medical Systems (INSP) is presented as an attractive takeover target due to its solid financials, strong balance sheet, and innovative neurostimulation technology for sleep apnea. The article identifies Medtronic, Boston Scientific, and Stryker as logical potential acquirers, estimating a deal value between $2.0 billion and $2.4 billion. It notes that INSP's dispersed ownership and lack of structural defenses make it an accessible target for a serious bidder.
Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement
Daré Bioscience has announced a definitive securities purchase agreement with institutional investors for a registered direct offering, expecting to raise approximately $6.0 million. The offering includes the sale of about 4.38 million shares of common stock at $1.37 per share, along with concurrent private placements of Series A and Series B warrants, which require stockholder approval to be exercisable. The closing is anticipated around August 17, 2026, and Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent.
Union Bancaire Privee UBP SA Sells 173,105 Shares of Boston Scientific Corporation $BSX
Union Bancaire Privee UBP SA significantly reduced its stake in Boston Scientific Corporation by selling 173,105 shares, retaining 62,129 shares valued at $2.6 million. Despite this, institutional investors collectively own 89.07% of the company, and insiders, including CEO Michael F. Mahoney, recently purchased over $9.94 million worth of shares. Boston Scientific also announced a $5 billion share-repurchase program and exceeded quarterly expectations with adjusted EPS of $0.86 and revenue of $5.44 billion, leading analysts to maintain a "Moderate Buy" rating.
The Beat: Target names AI chief, Niron gets White House backing, Envoy chases cochlear market
Target Corp. has appointed Chandhu Nair as its first chief AI officer, signaling a significant investment in artificial intelligence. Separately, Minnesota-based Niron Magnetics secured a $150 million loan from the White House, while Envoy Medical is looking to disrupt the $2.9 billion cochlear implant market. These developments highlight major moves in retail technology, advanced manufacturing, and medical technology sectors.
Teleflex (TFX) Q2 2026 Earnings Call Transcript
Teleflex reported a 4.7% increase in pro forma adjusted constant currency revenue for Q2 2026, driven by strong Vascular and Surgical segment performance, despite Interventional segment integration challenges. The company completed a $1.5 billion OEM divestiture to fund debt reduction and share repurchases, and it raised its full-year adjusted EPS guidance due to lower interest expenses and share buybacks. Teleflex also highlighted the FDA approval of EZPLAZ and advancements in its Freesolve clinical trials, emphasizing a strategic shift toward core critical care and high-acuity markets.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
This article analyzes Boston Scientific (BSX) recommendations, noting that while brokerage firms give it a "Strong Buy" average, the Zacks Rank rates it a "Strong Sell." It highlights the potential bias in brokerage recommendations due to vested interests and advises investors to consider the Zacks Rank's earnings estimate revisions for a more reliable indicator of stock performance.
Boston Scientific Corporation $BSX Shares Acquired by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd significantly increased its stake in Boston Scientific Corporation by 148.8% in Q2, acquiring 670,060 additional shares to reach a total of 1.12 million shares valued at $47.8 million. Insiders also showed confidence, with CEO Michael Mahoney purchasing 186,240 shares for $9 million. The company reported strong Q2 earnings, exceeding analyst expectations with $0.86 EPS and $5.44 billion in revenue, maintaining a "Moderate Buy" consensus rating and a $71.62 average price target.
QRG Capital Management Inc. Buys 198,951 Shares of Boston Scientific Corporation $BSX
QRG Capital Management Inc. significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 121.5% in the second quarter, acquiring 198,951 additional shares and bringing its total holdings to 362,716 shares valued at $15.5 million. This comes amidst strong financial performance from Boston Scientific, which exceeded Q2 earnings and revenue expectations with an EPS of $0.86 and $5.44 billion in revenue, alongside a 7.5% year-over-year revenue growth. The company also announced a $5 billion share repurchase program, and insiders, including CEO Michael Mahoney, have made substantial share purchases, reinforcing a "Moderate Buy" consensus rating among analysts.
NewEdge Advisors LLC Sells 27,583 Shares of Boston Scientific Corporation $BSX
NewEdge Advisors LLC reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 29.6% in the first quarter, selling 27,583 shares and retaining 65,461 shares valued at $4.1 million. Despite some recent price target reductions from analysts, the company maintains an average "Moderate Buy" rating. Boston Scientific also surpassed quarterly expectations with strong EPS and revenue growth, and authorized a $5 billion share-repurchase program.
Boston Scientific Corporation $BSX Shares Purchased by Fisher Funds Management LTD
Fisher Funds Management LTD significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 17.1% in the second quarter, bringing its total holding to approximately $43 million. This comes as institutional investors collectively own 89.07% of BSX. Boston Scientific recently reported strong quarterly revenue and EPS, exceeding analyst expectations, and authorized a $5 billion share-repurchase program, signaling confidence in the company's valuation.
Brookstone Capital Management Sells 233,448 Shares of Boston Scientific Corporation $BSX
Brookstone Capital Management significantly reduced its stake in Boston Scientific, selling 233,448 shares and retaining a smaller position. Despite this sale, institutional investors still hold a large percentage of the company, and analysts maintain a "Moderate Buy" rating. Boston Scientific recently surpassed quarterly earnings expectations and authorized a $5 billion share repurchase program.
Boston Scientific Corp (BSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Boston Scientific Corp (BSX), detailing its current price momentum score, support and resistance levels, and various technical indicator readings. It also includes an analysis of moving averages and addresses frequently asked questions regarding technical ratings and moving averages. The analysis suggests a neutral signal based on moving averages and other technical indicators.
Boston Scientific's CEO Bought $9M of His Own Stock
Boston Scientific's CEO, Michael Mahoney, purchased approximately $9 million of his company's stock, with two directors also buying shares and no 10b5-1 plan in place. Additionally, CoStar founder-CEO Andrew Florance bought about $2.5 million of his own stock. The article also notes that President Trump's stock trades are now available on the Quiver API.
Boston Scientific (BSX) SVP Emily Woodworth adds 2,930 shares in 401(k) rebalance
Emily Woodworth, SVP, Global Controller and CAO at Boston Scientific (BSX), acquired 2,930 shares of common stock at $51.19 per share through a 401(k) rebalance on August 11, 2026. This transaction increased her indirect 401(k) holdings to 2,930 shares, in addition to her 3,123 directly held shares. The acquisition was a discretionary transaction under Rule 16b-3(f) and was not made under a Rule 10b5-1 trading plan.
Fractyl Health at Canaccord conference: betting on post-glp-1 care
Fractyl Health presented at Canaccord Genuity's 46th Annual Growth Conference, outlining its focus on developing durable metabolic treatments for obesity and type 2 diabetes, particularly for post-GLP-1 weight maintenance. The company highlighted promising clinical data for its lead program, Revita, which is now in a pivotal study, and the advancement of its gene therapy candidate, Rejuva, towards first-in-human testing. Fractyl Health aims for a targeted commercial model through centers of excellence, addressing a significant unmet need in long-term weight management.
Fractyl Health at Canaccord conference: betting on post-glp-1 care
Fractyl Health presented at Canaccord Genuity’s 46th Annual Growth Conference, outlining its strategy to develop durable metabolic treatments for obesity and type 2 diabetes, focusing on post-GLP-1 care. The company highlighted promising clinical data for its lead asset, Revita, a duodenal resurfacing device, and the advancement of Rejuva, a pancreatic gene therapy. Fractyl plans a targeted commercial model through centers of excellence and anticipates key clinical data readouts and regulatory filings by year-end and early next year.
Cheniere Energy (NYSE:LNG) Stock Forecast & Analyst Predictions
Cheniere Energy (NYSE:LNG) is projected to grow earnings by 7.1% and revenue by 5.8% annually. The company recently raised its 2026 earnings guidance and reported strong Q2 2026 results, exceeding analyst expectations. Expansion projects at Corpus Christi and Sabine Pass are advancing, aiming to significantly increase LNG production capacity, despite some analyst revisions to EPS forecasts and ongoing federal investigations.
Northside Capital Management LLC Purchases 49,189 Shares of Boston Scientific Corporation $BSX
Northside Capital Management LLC significantly increased its stake in Boston Scientific Corporation by 44.2% in the second quarter, bringing its total holdings to 160,366 shares valued at $6.84 million. The medical equipment provider has a consensus "Moderate Buy" rating from analysts and recently reported strong quarterly earnings, exceeding expectations with adjusted EPS of $0.86 and revenue of $5.44 billion, alongside authorizing a $5 billion share buyback program. Institutional investors hold 89.07% of the company's stock, and recent insider activity shows directors acquiring shares.
How MiRus got $1.5B Boston Scientific investment for heart valve - Atlanta Business Chronicle
Marietta-based MiRus, led by Dr. Jay Yadav, has secured a $1.5 billion investment from Boston Scientific for its heart valve replacement technology. The company is pursuing FDA approval for its innovative heart valve, which utilizes a superalloy, driven by Yadav's personal motivation and past entrepreneurial successes. This significant investment highlights the growing innovation in Georgia's life sciences sector.
Boston Scientific Corporation $BSX Shares Sold by E. Ohman J or Asset Management AB
E. Ohman J or Asset Management AB significantly reduced its stake in Boston Scientific Corporation, selling 91.4% of its shares in the second quarter. Despite this, institutional investors collectively own a substantial portion of the company, and insiders have made significant purchases. Boston Scientific reported strong quarterly earnings and revenue, exceeding analyst expectations, and has authorized a $5 billion share buyback program.
Boston Scientific (BSX) CFO adds 9,908 shares through discretionary 401(k) rebalancing
Jonathan Monson, EVP and CFO of Boston Scientific (BSX), acquired 9,908 shares of common stock on August 10, 2026, at $50.46 per share. This acquisition was a result of a discretionary rebalancing election within the company’s 401(k) Retirement Savings Plan. Following this transaction, Monson indirectly holds 9,908 shares through the 401(k) and directly holds an additional 39,063 shares.
Boston Scientific Corp. stock outperforms competitors on strong trading day
Boston Scientific Corp. (BSX) saw its stock rise by 1.45% to $51.19 on Tuesday, marking its fourth consecutive day of gains. This performance occurred despite a general market downturn, with both the S&P 500 Index and Dow Jones Industrial Average experiencing declines. The company's stock outperformed its competitors on a challenging trading day.
Penumbra, Inc. (PEN) Stock Analysis: Evaluating the 11.45% Potential Upside in Medical Devices
Penumbra, Inc. (NYSE: PEN), a medical devices company with a $12.79 billion market cap, shows a potential upside of 11.45% based on analyst target prices. Despite a premium valuation with a forward P/E of 52.95, the company exhibits strong performance with 14.90% revenue growth and robust free cash flow, reinvesting profits for innovation rather than paying dividends. Technical indicators suggest positive momentum, though the stock might be overbought, making it a compelling option for growth-oriented investors in the healthcare sector.
Becton, Dickinson and Company (BDX) Stock forecasts
This article provides a stock forecast for
Boston Scientific Stock And 2 Low Volatility Picks For A Slower US Economy
Amidst growing concerns about a slower U.S. economy, this article identifies three low-volatility stocks—Boston Scientific (BSX), Aon (AON), and CorVel (CRVL)—that are well-positioned for resilience. Boston Scientific benefits from essential medical procedures, Aon from its risk management services, and CorVel from its debt-free status and growth in medical cost management. The piece highlights that while these stocks offer stability, investors should also consider their specific risks and valuations.
